Wheels Up Experience Inc. filed its third-quarter 2026 financial results on November 5, 2026, reporting GAAP revenue of $164.8 million and a net loss of $89.4 million, alongside a new $100 million revolving credit facility commitment from Delta Air Lines and a landmark order …
DTE Energy filed an 8-K earnings announcement on November 5, 2026, disclosing a roughly $3 billion agreement to sell its non-utility DTE Vantage business and reporting third quarter 2026 net earnings of $470 million, or $2.25 per diluted share.
Virtu Financial, Inc. filed a Form 8-K on November 5, 2026, disclosing that its Board of Directors approved a Plan of Conversion to reincorporate the company from Delaware to Texas, and separately reporting financial results for the quarter ended September 30, 2026.
Eos Energy Enterprises, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 5, 2026, reporting condensed consolidated financial results and balance sheet data for the three and nine months ended September …
Wheels Up Experience Inc. filed an 8-K on November 5, 2026, announcing a definitive agreement with Embraer to purchase six factory-new Phenom 300E premium light jets for delivery in the second half of 2027.
BP p.l.c. filed a Form 6-K with the SEC on 5 November 2026 disclosing the sale of a 5% stake in Aker BP at NOK 311 per share, raising gross proceeds of approximately NOK 9.83 billion ($1.06 billion).
DTE Energy Company filed a Form 8-K with the SEC on November 5, 2026, furnishing its earnings release and slide presentation announcing financial results for the quarter ended September 30, 2026.
Chimera Investment Corporation filed a current report on November 5, 2026, disclosing the release of its financial results for the quarter ended September 30, 2026, along with an accompanying investor presentation.
Zai Lab Limited filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 5, 2026, covering the three and nine months ended September 30, 2026.
Eli Lilly and Company issued an 8-K press release on November 5, 2026, disclosing new Phase 3 clinical trial results for retatrutide and for the combination of Taltz and Zepbound, to be presented at the American College of Rheumatology Convergence 2026 conference beginning November …